Identification
- Generic Name
- Butyric Acid
- DrugBank Accession Number
- DB03568
- Background
A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Butyric Acid (DB03568)
- Weight
- Average: 88.1051
Monoisotopic: 88.0524295 - Chemical Formula
- C4H8O2
- Synonyms
- 1-propanecarboxylic acid
- Butanoic acid
- Butyrate
- Butyricum acidum
- Ethylacetic acid
- N-butanoic acid
- N-butyric acid
- Propylformic acid
- External IDs
- FEMA NO. 2221
- NSC-8415
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism U(S)-2-haloacid dehalogenase Not Available Pseudomonas sp. (strain YL) UCholinesterase Not Available Humans U2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase Not Available Pseudomonas fluorescens - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Butyrate Metabolism Metabolic Fatty Acid Biosynthesis Metabolic - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sodium butyrate 8RAS91C36W 156-54-7 MFBOGIVSZKQAPD-UHFFFAOYSA-M α-keto-γ-methylselenobutyrate Not Available Not Available Not applicable
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as straight chain fatty acids. These are fatty acids with a straight aliphatic chain.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- Sub Class
- Fatty acids and conjugates
- Direct Parent
- Straight chain fatty acids
- Alternative Parents
- Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic oxide / Organic oxygen compound / Organooxygen compound / Straight chain fatty acid
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- straight-chain saturated fatty acid, short-chain fatty acid (CHEBI:30772) / Straight chain fatty acids, Saturated fatty acids (C00246) / Straight chain fatty acids (LMFA01010004)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 40UIR9Q29H
- CAS number
- 107-92-6
- InChI Key
- FERIUCNNQQJTOY-UHFFFAOYSA-N
- InChI
- InChI=1S/C4H8O2/c1-2-3-4(5)6/h2-3H2,1H3,(H,5,6)
- IUPAC Name
- butanoic acid
- SMILES
- CCCC(O)=O
References
- Synthesis Reference
Haruhiko Kikuchi, "Process for preparing 4-(4-biphenylyl)-4-oxo-butanoic acid." U.S. Patent US4621154, issued November, 1977.
US4621154- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000039
- KEGG Compound
- C00246
- PubChem Compound
- 264
- PubChem Substance
- 46505927
- ChemSpider
- 259
- BindingDB
- 26109
- 1362696
- ChEBI
- 30772
- ChEMBL
- CHEMBL14227
- ZINC
- ZINC000000895132
- Guide to Pharmacology
- GtP Drug Page
- PDBe Ligand
- BUA
- Wikipedia
- Butyric_acid
- PDB Entries
- 1p0i / 1ugp / 1uk7 / 1zrm / 2cz0 / 2cz1 / 2ha7 / 2j4c / 3dlt / 3i3f … show 19 more
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Alcohol Dependency / Alcohol Use Disorders (AUD) 1 4 Completed Treatment Alcohol Dependency / Alcohol Withdrawal Syndrome 1 4 Completed Treatment Atopic Dermatitis 1 4 Recruiting Treatment Epilepsy 1 3 Completed Treatment Type 1 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Not applicable 1 g/1g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) -5.7 °C PhysProp boiling point (°C) 163.7 °C PhysProp water solubility 6E+004 mg/L (at 25 °C) HEMPHILL,L & SWANSON,WS (1964) logP 0.79 HANSCH,C ET AL. (1995) logS -0.19 ADME Research, USCD pKa 4.82 (at 25 °C) RIDDICK,JA ET AL. (1986) - Predicted Properties
Property Value Source Water Solubility 239.0 mg/mL ALOGPS logP 0.78 ALOGPS logP 0.92 Chemaxon logS 0.43 ALOGPS pKa (Strongest Acidic) 4.91 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 37.3 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 21.87 m3·mol-1 Chemaxon Polarizability 9.22 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9938 Blood Brain Barrier + 0.9572 Caco-2 permeable + 0.7456 P-glycoprotein substrate Non-substrate 0.759 P-glycoprotein inhibitor I Non-inhibitor 0.9554 P-glycoprotein inhibitor II Non-inhibitor 0.9773 Renal organic cation transporter Non-inhibitor 0.9544 CYP450 2C9 substrate Non-substrate 0.8026 CYP450 2D6 substrate Non-substrate 0.9177 CYP450 3A4 substrate Non-substrate 0.7582 CYP450 1A2 substrate Inhibitor 0.5106 CYP450 2C9 inhibitor Non-inhibitor 0.9345 CYP450 2D6 inhibitor Non-inhibitor 0.9519 CYP450 2C19 inhibitor Non-inhibitor 0.9613 CYP450 3A4 inhibitor Non-inhibitor 0.972 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9849 Ames test Non AMES toxic 0.95 Carcinogenicity Non-carcinogens 0.5611 Biodegradation Ready biodegradable 0.9659 Rat acute toxicity 1.6755 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9484 hERG inhibition (predictor II) Non-inhibitor 0.9677
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 110.0611425 predictedDarkChem Lite v0.1.0 [M-H]- 110.0099425 predictedDarkChem Lite v0.1.0 [M-H]- 110.1456425 predictedDarkChem Lite v0.1.0 [M-H]- 131.852 predictedDeepCCS 1.0 (2019) [M+H]+ 134.64949 predictedDeepCCS 1.0 (2019) [M+Na]+ 142.87775 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Pseudomonas sp. (strain YL)
- Pharmacological action
- Unknown
- General Function
- (s)-2-haloacid dehalogenase activity
- Specific Function
- Catalyzes the hydrolytic dehalogenation of small (S)-2-haloalkanoic acids to yield the corresponding (R)-2-hydroxyalkanoic acids. Acts on acids of short chain lengths, C(2) to C(4), with inversion ...
- Gene Name
- Not Available
- Uniprot ID
- Q53464
- Uniprot Name
- (S)-2-haloacid dehalogenase
- Molecular Weight
- 26176.335 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Identical protein binding
- Specific Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
- Kind
- Protein
- Organism
- Pseudomonas fluorescens
- Pharmacological action
- Unknown
- General Function
- Hydrolase activity
- Specific Function
- Not Available
- Gene Name
- cumD
- Uniprot ID
- P96965
- Uniprot Name
- 2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase
- Molecular Weight
- 31489.385 Da
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Ligand
- General Function
- Identical protein binding
- Specific Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Xu YL, Li FY, Ndikuryayo F, Yang WC, Wang HM: Cholinesterases and Engineered Mutants for the Detection of Organophosphorus Pesticide Residues. Sensors (Basel). 2018 Dec 5;18(12). pii: s18124281. doi: 10.3390/s18124281. [Article]
- Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM: Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013 May;11(3):315-35. doi: 10.2174/1570159X11311030006. [Article]
- Casper D, Davies P: Stimulation of choline acetyltransferase activity by retinoic acid and sodium butyrate in a cultured human neuroblastoma. Brain Res. 1989 Jan 23;478(1):74-84. doi: 10.1016/0006-8993(89)91478-9. [Article]
Drug created at June 13, 2005 13:24 / Updated at November 21, 2021 16:25